DK2234645T3 - Peg-interferon-beta-formuleringer - Google Patents

Peg-interferon-beta-formuleringer

Info

Publication number
DK2234645T3
DK2234645T3 DK08863833T DK08863833T DK2234645T3 DK 2234645 T3 DK2234645 T3 DK 2234645T3 DK 08863833 T DK08863833 T DK 08863833T DK 08863833 T DK08863833 T DK 08863833T DK 2234645 T3 DK2234645 T3 DK 2234645T3
Authority
DK
Denmark
Prior art keywords
peg
interferon
surfactant
buffer
beta formulations
Prior art date
Application number
DK08863833T
Other languages
English (en)
Inventor
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of DK2234645T3 publication Critical patent/DK2234645T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK08863833T 2007-12-20 2008-12-18 Peg-interferon-beta-formuleringer DK2234645T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07150258 2007-12-20
US1025808P 2008-01-07 2008-01-07
PCT/EP2008/067876 WO2009080699A2 (en) 2007-12-20 2008-12-18 Peg-interferon-beta formulations

Publications (1)

Publication Number Publication Date
DK2234645T3 true DK2234645T3 (da) 2012-07-09

Family

ID=39760852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08863833T DK2234645T3 (da) 2007-12-20 2008-12-18 Peg-interferon-beta-formuleringer

Country Status (20)

Country Link
US (1) US9138403B2 (da)
EP (1) EP2234645B1 (da)
JP (2) JP5563475B2 (da)
KR (1) KR20100099298A (da)
CN (1) CN101878043A (da)
AT (1) ATE555812T1 (da)
AU (1) AU2008340058A1 (da)
BR (1) BRPI0821029A2 (da)
CY (1) CY1112820T1 (da)
DK (1) DK2234645T3 (da)
EA (1) EA201070773A1 (da)
ES (1) ES2387236T3 (da)
HR (1) HRP20120483T1 (da)
IL (1) IL206441A0 (da)
PL (1) PL2234645T3 (da)
PT (1) PT2234645E (da)
RS (1) RS52417B (da)
SI (1) SI2234645T1 (da)
WO (1) WO2009080699A2 (da)
ZA (1) ZA201001908B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2234645T1 (sl) * 2007-12-20 2012-07-31 Merck Serono Sa Formulacije peg interferon beta
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
US20140308239A1 (en) * 2013-03-13 2014-10-16 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
WO2016052584A1 (ja) * 2014-09-30 2016-04-07 東レ株式会社 ポリエチレングリコール修飾インターフェロン－βの検出及び定量に使用する試料液の前処理方法、ポリエチレングリコール修飾インターフェロン－βの検出方法及び定量方法
KR20170081257A (ko) * 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 C형 간염에 대한 조합 장기 작용 조성물 및 방법
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN116023466B (zh) * 2023-03-30 2023-06-27 北京生物制品研究所有限责任公司 纯化PEG修饰重组人干扰素β1b蛋白的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4469228A (en) * 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR950014915B1 (ko) * 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
US5858001A (en) * 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
SK284989B6 (sk) 1996-12-24 2006-04-06 Biogen, Inc. Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
IL136326A0 (en) * 1997-12-08 2001-05-20 Genentech Inc Human interferon-epsilon: a type i interferon
PT1066059E (pt) 1998-03-26 2005-10-31 Schering Corp Formulacoes para proteccao de conjugados de peg-interferao alfa
ES2224649T3 (es) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
IL142282A0 (en) 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2002003430A2 (en) 2000-06-29 2002-01-10 California Institute Of Technology Aerosol process for fabricating discontinuous floating gate microelectronic devices
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
AU2002219198B2 (en) 2000-12-27 2006-06-29 Ares Trading S.A. Lipid microparticles by cryogenic micronization
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP2004522803A (ja) * 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
EP1471891A4 (en) 2002-02-08 2007-04-11 Alkermes Inc POLYMER-BASED COMPOSITIONS FOR PROLONGED RELEASE
AU2002357557A1 (en) * 2002-05-14 2003-11-11 Beijing Jiankai Technology Co. Ltd. Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
EP1553971A4 (en) * 2002-07-17 2006-07-05 Biogen Idec Inc THERAPIES AGAINST KIDNEY FAILURES WITH INTERFERON-b
AU2003294757A1 (en) 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
RS20050502A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1628686A2 (en) * 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US7691975B2 (en) * 2003-08-25 2010-04-06 Toray Industries, Inc. Interferon-β complex
RS52218B (en) * 2003-12-11 2012-10-31 Ares Trading S.A. STABILIZED FLUID INTERFERON FORMULATIONS
WO2005084303A2 (en) * 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
EA012205B1 (ru) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
BRPI0510526A (pt) 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
US7632491B2 (en) * 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
SI2234645T1 (sl) * 2007-12-20 2012-07-31 Merck Serono Sa Formulacije peg interferon beta

Also Published As

Publication number Publication date
JP5563475B2 (ja) 2014-07-30
WO2009080699A2 (en) 2009-07-02
KR20100099298A (ko) 2010-09-10
JP2014159445A (ja) 2014-09-04
AU2008340058A1 (en) 2009-07-02
IL206441A0 (en) 2010-12-30
ATE555812T1 (de) 2012-05-15
EA201070773A1 (ru) 2010-12-30
JP2011506562A (ja) 2011-03-03
ES2387236T3 (es) 2012-09-18
US20100239529A1 (en) 2010-09-23
PL2234645T3 (pl) 2012-10-31
BRPI0821029A2 (pt) 2015-06-16
WO2009080699A3 (en) 2009-11-26
CN101878043A (zh) 2010-11-03
CY1112820T1 (el) 2016-02-10
HRP20120483T1 (hr) 2012-07-31
EP2234645B1 (en) 2012-05-02
RS52417B (en) 2013-02-28
US9138403B2 (en) 2015-09-22
ZA201001908B (en) 2011-05-25
PT2234645E (pt) 2012-05-21
EP2234645A2 (en) 2010-10-06
SI2234645T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
CY1112820T1 (el) Φαρμακοτεχνικες μορφες της ρεg-ιντερφερονης-βητα
AR108998A2 (es) Composición farmacéutica que contiene neurotoxina botulínica
RS51592B (en) SOLID PREPARATION CONTAINING ALOGLIPTIN AND PIOGLITAZONE
NZ600096A (en) Formulations of antibody
AU2009215514A9 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
MX2010009850A (es) Analogos de insulina acilados y etabilizados contra proteasas.
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
MEP18208A (en) Immune response modifier foam formulations
DK1475101T3 (da) Antistof-holdige farmaceutiske opløsninger
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
EA201070689A1 (ru) Композиция для личного ухода
DK2038294T3 (da) 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse
MY153391A (en) Composition for controlling parasites on animals
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
FR2894980B1 (fr) Compositions aqueuses epaissantes et limpides, leur utilisation dans des formulations aqueuses acides, formulations obtenues.
WO2009087175A3 (en) Allergy vaccine composition for mucosal administration
WO2007014964A3 (de) Kosmetische und pharmazeutische mittel enthaltend isoalkanolalkoxilate
TH0801002717B (th) สารต้านทานความเหนื่อยล้าและองค์ประกอบให้ทางปากที่ประกอบด้วยแอนโดรกราโฟไลด์ในรูปส่วนผสมออกฤทธิ์
ITMI20061883A1 (it) Formulazioni orodispersibili, gastroprotettive e taste- masking contenenti almeno un principio attivo gastrolesivo